DJ Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. $(INCY)$ slipped 1.25% to $57.73 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 2.24% to 5,275.70 and Dow Jones Industrial Average falling 1.73% to 39,669.39.
This was the stock's second consecutive day of losses.
Incyte Corp. closed 31.23% short of its 52-week high of $83.95, which the company achieved on November 8th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ fell 0.19% to $230.50, Bio-Techne Corp. $(TECH)$ fell 2.14% to $49.98, and BioMarin Pharmaceutical Inc. $(BMRN)$ fell 2.00% to $58.82.
Trading volume (1.5 M) remained 665,671 below its 50-day average volume of 2.1 M.
Data source: Dow Jones Market Data, FactSet. Data compiled April 16, 2025.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 16, 2025 17:18 ET (21:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。